Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Shire
Pharma
FDA signs off on Takeda's HyQvia as maintenance therapy for CIDP
The FDA has approved Takeda's HyQvia as a maintenance therapy for CIDP. It is the second indication for HyQvia, which was first endorsed in 2014.
Kevin Dunleavy
Jan 16, 2024 11:12am
Takeda pays €130M to settle AbbVie-Shire breakup fee
Oct 18, 2023 11:30am
Studies show advantages for Supernus' Qelbree in kids and adults
Sep 11, 2023 2:11pm
Takeda shells out $42M to settle Medicaid fraud claims in Texas
Aug 9, 2023 11:41am
Takeda is calling it quits on Natpara's US commercial return
Oct 4, 2022 2:35pm
Novo Nordisk's semaglutide misses the mark in NASH study
Jun 29, 2022 10:53am
